Positron emission tomography imaging in evaluation of cancer patients

R. Kumar, Peeyush Bhargava, M. F. Bozkurt, H. Zhuang, S. Potenta, A. Alavi

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Positron emission tomography (PET) is a diagnostic imaging technique that has progressed rapidly from being a research technique in laboratories to a routine clinical imaging modality. The most widely used radiotracer in PET is Fluorine18-fluorodeoxyglucose (F18-FDG), which is an analogue of glucose. The FDG uptake in cells is directly proportional to glucose metabolism of cells. Since glucose metabolism is increased many fold in malignant tumors PET has a high sensitivity and a high negative predictive value. PET with FDG is now the standard of care in initial staging, monitoring the response to the therapy, and management of lung cancer, colonic cancer, lymphoma, melanoma, esophageal cancer, head and neck cancer and breast cancer. Other indications of PET like bone tumor, ovarian cancer and cancer of unknown primary (CUP) has also been discussed in brief. The aim of this review article is to review the clinical applications of PET in various malignancies and only limited number of important studies will be discussed for this effort.

Original languageEnglish (US)
Pages (from-to)87-100
Number of pages14
JournalIndian Journal of Cancer
Volume40
Issue number3
StatePublished - Jul 1 2003
Externally publishedYes

Fingerprint

Positron-Emission Tomography
Neoplasms
Head and Neck Neoplasms
Glucose
Breast Neoplasms
Diagnostic Imaging
Standard of Care
Esophageal Neoplasms
Ovarian Neoplasms
Colonic Neoplasms
Melanoma
Lymphoma
Lung Neoplasms
Research Design
Bone and Bones

Keywords

  • Breast cancer
  • Colonic cancer
  • Fluorodeoxyglucose
  • Gastric and esophageal cancer
  • Head and neck cancer
  • Lung nodule and lung cancer
  • Lymphoma
  • Melanoma
  • Ovarian cancer
  • Positron emission tomography

ASJC Scopus subject areas

  • Oncology

Cite this

Kumar, R., Bhargava, P., Bozkurt, M. F., Zhuang, H., Potenta, S., & Alavi, A. (2003). Positron emission tomography imaging in evaluation of cancer patients. Indian Journal of Cancer, 40(3), 87-100.

Positron emission tomography imaging in evaluation of cancer patients. / Kumar, R.; Bhargava, Peeyush; Bozkurt, M. F.; Zhuang, H.; Potenta, S.; Alavi, A.

In: Indian Journal of Cancer, Vol. 40, No. 3, 01.07.2003, p. 87-100.

Research output: Contribution to journalReview article

Kumar, R, Bhargava, P, Bozkurt, MF, Zhuang, H, Potenta, S & Alavi, A 2003, 'Positron emission tomography imaging in evaluation of cancer patients', Indian Journal of Cancer, vol. 40, no. 3, pp. 87-100.
Kumar R, Bhargava P, Bozkurt MF, Zhuang H, Potenta S, Alavi A. Positron emission tomography imaging in evaluation of cancer patients. Indian Journal of Cancer. 2003 Jul 1;40(3):87-100.
Kumar, R. ; Bhargava, Peeyush ; Bozkurt, M. F. ; Zhuang, H. ; Potenta, S. ; Alavi, A. / Positron emission tomography imaging in evaluation of cancer patients. In: Indian Journal of Cancer. 2003 ; Vol. 40, No. 3. pp. 87-100.
@article{2a5bd4dc7f044027b41c80ca11246360,
title = "Positron emission tomography imaging in evaluation of cancer patients",
abstract = "Positron emission tomography (PET) is a diagnostic imaging technique that has progressed rapidly from being a research technique in laboratories to a routine clinical imaging modality. The most widely used radiotracer in PET is Fluorine18-fluorodeoxyglucose (F18-FDG), which is an analogue of glucose. The FDG uptake in cells is directly proportional to glucose metabolism of cells. Since glucose metabolism is increased many fold in malignant tumors PET has a high sensitivity and a high negative predictive value. PET with FDG is now the standard of care in initial staging, monitoring the response to the therapy, and management of lung cancer, colonic cancer, lymphoma, melanoma, esophageal cancer, head and neck cancer and breast cancer. Other indications of PET like bone tumor, ovarian cancer and cancer of unknown primary (CUP) has also been discussed in brief. The aim of this review article is to review the clinical applications of PET in various malignancies and only limited number of important studies will be discussed for this effort.",
keywords = "Breast cancer, Colonic cancer, Fluorodeoxyglucose, Gastric and esophageal cancer, Head and neck cancer, Lung nodule and lung cancer, Lymphoma, Melanoma, Ovarian cancer, Positron emission tomography",
author = "R. Kumar and Peeyush Bhargava and Bozkurt, {M. F.} and H. Zhuang and S. Potenta and A. Alavi",
year = "2003",
month = "7",
day = "1",
language = "English (US)",
volume = "40",
pages = "87--100",
journal = "Indian Journal of Cancer",
issn = "0019-509X",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "3",

}

TY - JOUR

T1 - Positron emission tomography imaging in evaluation of cancer patients

AU - Kumar, R.

AU - Bhargava, Peeyush

AU - Bozkurt, M. F.

AU - Zhuang, H.

AU - Potenta, S.

AU - Alavi, A.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Positron emission tomography (PET) is a diagnostic imaging technique that has progressed rapidly from being a research technique in laboratories to a routine clinical imaging modality. The most widely used radiotracer in PET is Fluorine18-fluorodeoxyglucose (F18-FDG), which is an analogue of glucose. The FDG uptake in cells is directly proportional to glucose metabolism of cells. Since glucose metabolism is increased many fold in malignant tumors PET has a high sensitivity and a high negative predictive value. PET with FDG is now the standard of care in initial staging, monitoring the response to the therapy, and management of lung cancer, colonic cancer, lymphoma, melanoma, esophageal cancer, head and neck cancer and breast cancer. Other indications of PET like bone tumor, ovarian cancer and cancer of unknown primary (CUP) has also been discussed in brief. The aim of this review article is to review the clinical applications of PET in various malignancies and only limited number of important studies will be discussed for this effort.

AB - Positron emission tomography (PET) is a diagnostic imaging technique that has progressed rapidly from being a research technique in laboratories to a routine clinical imaging modality. The most widely used radiotracer in PET is Fluorine18-fluorodeoxyglucose (F18-FDG), which is an analogue of glucose. The FDG uptake in cells is directly proportional to glucose metabolism of cells. Since glucose metabolism is increased many fold in malignant tumors PET has a high sensitivity and a high negative predictive value. PET with FDG is now the standard of care in initial staging, monitoring the response to the therapy, and management of lung cancer, colonic cancer, lymphoma, melanoma, esophageal cancer, head and neck cancer and breast cancer. Other indications of PET like bone tumor, ovarian cancer and cancer of unknown primary (CUP) has also been discussed in brief. The aim of this review article is to review the clinical applications of PET in various malignancies and only limited number of important studies will be discussed for this effort.

KW - Breast cancer

KW - Colonic cancer

KW - Fluorodeoxyglucose

KW - Gastric and esophageal cancer

KW - Head and neck cancer

KW - Lung nodule and lung cancer

KW - Lymphoma

KW - Melanoma

KW - Ovarian cancer

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=1442281809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442281809&partnerID=8YFLogxK

M3 - Review article

VL - 40

SP - 87

EP - 100

JO - Indian Journal of Cancer

JF - Indian Journal of Cancer

SN - 0019-509X

IS - 3

ER -